FABP3 protein promotes α-synuclein oligomerization associated with 1-Methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity

Journal of Biological Chemistry

Volumn 289, Issue 27, 2014, Pages 18957-18965

  Shioda, Norifumi ^a   Yabuki, Yasushi ^a   Kobayashi, Yuka ^a   Onozato, Misaki ^a   Owada, Yuji ^b   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; OLIGOMERIZATION; OLIGOMERS;

NEURONAL TOXICITY; NEUROTOXICITY; SYNUCLEIN;

TOXICITY;

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MOTOR PERFORMANCE; MOUSE; MPTP-INDUCED PARKINSONISM; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SUBSTANTIA NIGRA PARS COMPACTA;

CELL DEATH; DOPAMINE; DOPAMINERGIC NEURON; FATTY ACID-BINDING PROTEIN; FATTY ACID-BINDING PROTEIN 3; PARKINSON DISEASE; POLYUNSATURATED FATTY ACID (PUFA); Α-SYNUCLEIN;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALPHA-SYNUCLEIN; ANIMALS; ARACHIDONIC ACID; CELL DEATH; DOPAMINERGIC NEURONS; FATTY ACID-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; KINETICS; MICE; MOTOR ACTIVITY; MPTP POISONING; NEOSTRIATUM; NEUROTOXINS; PC12 CELLS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RATS; SUBSTANTIA NIGRA;

EID: 84903852279     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.527341     Document Type: Article

References (44)

1. de Lau, L. M., and Breteler, M. M. (2006) Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525-535
2. Dauer, W., and Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909
3. Maroteaux, L., Campanelli, J. T., and Scheller, R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815
4. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998) -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 95, 6469-6473
5. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn- Hardy, K. (2003)-Synuclein locus triplication causes Parkinson's disease. Science 302, 841
6. Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., Waucquier, N., Defebvre, L., Amouyel, P., Farrer, M., and Destée, A. (2004) -Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169
7. Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D. S., Hulihan, M., Maraganore, D., Gwinn-Hardy, K., Wszolek, Z., Dickson, D., and Langston, J. W. (2004) Comparison of kindreds with parkinsonism and -synuclein genomic multiplications. Ann. Neurol. 55, 174-179
8. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Mutation in the -synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047
9. Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schöls, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108
10. Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampu-ero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Muñoz, D. G., and de Yebenes, J. G. (2004) The new mutation, E46K, of -synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173
11. Proukakis, C., Dudzik, C. G., Brier, T., MacKay, D. S., Cooper, J. M., Millhauser, G. L., Houlden, H., and Schapira, A. H. (2013) A novel-synuclein missense mutation in Parkinson disease. Neurology 80, 1062-1064
12. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., Pieri, L., Madiona, K., Dürr, A., Melki, R., Verny, C., Brice, A., and French Parkinson's Disease Genetics (PDG) Study Group (2013) G51D -synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol. 73, 459-471
13. Conway, K. A., Harper, J. D., and Lansbury, P. T. (1998) Accelerated in vitro fibril formation by a mutant -synuclein linked to early onset Parkinson disease. Nat. Med. 4, 1318-1320
14. Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., Tzitzilonis, C., Soragni, A., Jessberger, S., Mira, H., Consiglio, A., Pham, E., Masliah, E., Gage, F. H., and Riek, R. (2011) In vivo demonstration that -synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 108, 4194-4199
15. Perrin, R. J., Woods, W. S., Clayton, D. F., and George, J. M. (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 276, 41958-41962
16. Sharon, R., Goldberg, M. S., Bar-Josef, I., Betensky, R. A., Shen, J., and Selkoe, D. J. (2001)-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 98, 9110-9115
17. Sharon, R., Bar-Joseph, I., Mirick, G. E., Serhan, C. N., and Selkoe, D. J. (2003) Altered fatty acid composition of dopaminergic neurons expressing -synuclein and human brains with -synucleinopathies. J. Biol. Chem. 278, 49874-49881
18. Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., and Selkoe, D. J. (2003) The formation of highly soluble oligomers of -synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595
19. Assayag, K., Yakunin, E., Loeb, V., Selkoe, D. J., and Sharon, R. (2007) Polyunsaturated fatty acids induce -synuclein-related pathogenic changes in neuronal cells. Am. J. Pathol. 171, 2000-2011
20. Coe, N. R., and Bernlohr, D. A. (1998) Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim. Biophys. Acta 1391, 287-306
21. Owada, Y., and Kondo, H. (2003) in Fatty Acid Binding Proteins of the Brain (Duttaroy, A. K., and Spener, F., eds) pp. 253-264, Wiley-VCH, Weinheim, Germany
22. Hanhoff, T., Lücke, C., and Spener, F. (2002) Insights into binding of fatty acids by fatty acid binding proteins. Mol. Cell. Biochem. 239, 45-54
23. Murphy, E. J., Owada, Y., Kitanaka, N., Kondo, H., and Glatz, J. F. (2005) Brain arachidonic acid incorporation is decreased in heart fatty acid binding protein gene-ablated mice. Biochemistry 44, 6350-6360
24. Binas, B., Danneberg, H., McWhir, J., Mullins, L., and Clark, A. J. (1999) Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization. FASEB J. 13, 805-812
25. Ferguson, M. C., Nayyar, T., Deutch, A. Y., and Ansah, T. A. (2010) 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology 59, 31-36
26. Shioda, N., Yamamoto, Y., Watanabe, M., Binas, B., Owada, Y., and Fukunaga, K. (2010) Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain. J. Neurosci. 30, 3146-3155
27. Zimmerman, A. W., Rademacher, M., Rüterjans, H., Lücke, C., and Veerkamp, J. H. (1999) Functional and conformational characterization of new mutants of heart fatty acid-binding protein. Biochem. J. 344, 495-501
28. Nguyen, S. M., Lieven, C. J., and Levin, L. A. (2007) Simultaneous labeling of projecting neurons and apoptotic state. J. Neurosci. Methods 161, 281-284
29. Dettmer, U., Newman, A. J., Luth, E. S., Bartels, T., and Selkoe, D. (2013) In vivo cross-linking reveals principally oligomeric forms of -synuclein and -synuclein in neurons and non-neural cells. J. Biol. Chem. 288, 6371-6385
30. Owada, Y., Yoshimoto, T., and Kondo, H. (1996) Spatio-temporally differential expression of genes for three members of fatty acid binding proteins in developing and mature rat brains. J. Chem. Neuroanat. 12, 113-122
31. Golovko, M. Y., Rosenberger, T. A., Faergeman, N. J., Feddersen, S., Cole, N. B., Pribill, I., Berger, J., Nussbaum, R. L., and Murphy, E. J. (2006) Acyl-CoA synthetase activity links wild-type but not mutant -synuclein to brain arachidonate metabolism. Biochemistry 45, 6956-6966
32. Richieri, G. V., Ogata, R. T., Zimmerman, A. W., Veerkamp, J. H., and Kleinfeld, A. M. (2000) Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry 39, 7197-7204
33. Lücke, C., Gantz, D. L., Klimtchuk, E., and Hamilton, J. A. (2006) Interactions between fatty acids and -synuclein. J. Lipid Res. 47, 1714-1724
34. Kawano, T., Anrather, J., Zhou, P., Park, L., Wang, G., Frys, K. A., Kunz, A., Cho, S., Orio, M., and Iadecola, C. (2006) Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat. Med. 12, 225-229
35. Nicklas, W. J., Vyas, I., and Heikkila, R. E. (1985) Inhibition of NADHlinked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503-2508
36. Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G., and Anandatheerthavarada, H. K. (2008) Mitochondrial import and accumulation of -synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283, 9089-9100
37. Song, G. X., Shen, Y. H., Liu, Y. Q., Sun, W., Miao, L. P., Zhou, L. J., Liu, H. L., Yang, R., Kong, X. Q., Cao, K. J., Qian, L. M., and Sheng, Y. H. (2012) Overexpression of FABP3 promotes apoptosis through inducing mitochondrial impairment in embryonic cancer cells. J. Cell. Biochem. 113, 3701-3708
38. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenamyre, J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306
39. Fornai, F., Lenzi, P., Gesi, M., Ferrucci, M., Lazzeri, G., Busceti, C. L., Ruffoli, R., Soldani, P., Ruggieri, S., Alessandri, M. G., and Paparelli, A. (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23, 8955-8966
40. Chen, H., Zhang, S. M., Hernán, M. A., Willett, W. C., and Ascherio, A. (2003) Dietary intakes of fat and risk of Parkinson's disease. Am. J. Epidemiol. 157, 1007-1014
41. Julien, C., Berthiaume, L., Hadj-Tahar, A., Rajput, A. H., Bédard, P. J., Di Paolo, T., Julien, P., and Calon, F. (2006) Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem. Int. 48, 404-414
42. Basso, M., Giraudo, S., Corpillo, D., Bergamasco, B., Lopiano, L., and Fasano, M. (2004) Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4, 3943-3952
43. Mollenhauer, B., Steinacker, P., Bahn, E., Bibl, M., Brechlin, P., Schlossmacher, M. G., Locascio, J. J., Wiltfang, J., Kretzschmar, H. A., Poser, S., Trenkwalder, C., and Otto, M. (2007) Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener. Dis. 4, 366-375
44. Wada-Isoe, K., Imamura, K., Kitamaya, M., Kowa, H., and Nakashima, K. (2008) Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J. Neurol. Sci. 266, 20-24